avkАрхивъ внутренней медициныThe Russian Archives of Internal Medicine2226-67042411-6564“SINAPS” LLC10.20514/2226-6704-2022-12-6-422-429avk-1531Research ArticleОБЗОРНЫЕ СТАТЬИREVIEW ARTICLESИНТЕРЛЕЙКИН-1 — БИОЛОГИЧЕСКИЙ МАРКЕР ПРИ СЕРДЕЧНОЙ НЕДО СТАТОЧНОСТИInterleukin-1 is a Biological Marker in Heart Failurehttps://orcid.org/0000-0001-5416-8579АлиеваА. М.AlievaA. M.

Москва

Moscow

КисляковВ. А.KislyakovV. A.

Москва

Moscow

ВоронковаК. В.VoronkovaK. V.

Москва

Moscow

https://orcid.org/0000-0001-7479-418XРезникЕ. В.ReznikE. V.

Москва

Moscow

https://orcid.org/0000-0002-2500-197XАракелянР. А.ArakelyanR. A.

Роза Арамовна Аракелян

Москва

Rose A. Arakelyan

Moscow

Elmira.sharm@yandex.ruhttps://orcid.org/0000-0003-1794-9258СарыевМ. Н.SaryevM. N.

Москва

Moscow

https://orcid.org/0000-0003-1613-3716ВалиевР. К.ValievR. K.

Москва

Moscow

РахаевА. М.RakhaevA. M.

Нальчик

Nalchik

ГасановаЭ. Т.HasanovaE. T.

Москва

Moscow

https://orcid.org/0000-0002-8949-4523КаловаМ. Р.KalovaM. R.

Москва

Moscow

https://orcid.org/0000-0003-1699-0881НикитинИ. Г.NikitinI. G.

Москва

Moscow

ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России)РоссияFederal State Autonomous Educational Institution of Higher Education «Russian National Research Medical University named after N.I. Pirogov» of the Ministry of Health of RussiaRussian FederationГБУЗ МКНЦ им. А.С. Логинова ДЗМРоссияState budgetary institution of health care of the city of Moscow «Moscow Clinical Research Center named after A.S. Loginov» of the Moscow Department of HealthRussian FederationФедеральное казенное учреждение «Главное бюро медико-социальной экспертизы по кабардино-балкарской республике» Министерства труда и социальной защиты Российской ФедерацииРоссияFederal State Institution «Main Bureau of Medical and Social Expertise in the Kabardino-Balkarian Republic» of the Ministry of Labor and Social Protection of the Russian FederationRussian Federation202229112022126422429Copyright © Алиева А.М., Кисляков В.А., Воронкова К.В., Резник Е.В., Аракелян Р.А., Сарыев М.Н., Валиев Р.К., Рахаев А.М., Гасанова Э.Т., Калова М.Р., Никитин И.Г., 20222022Алиева А.М., Кисляков В.А., Воронкова К.В., Резник Е.В., Аракелян Р.А., Сарыев М.Н., Валиев Р.К., Рахаев А.М., Гасанова Э.Т., Калова М.Р., Никитин И.Г.Alieva A.M., Kislyakov V.A., Voronkova K.V., Reznik E.V., Arakelyan R.A., Saryev M.N., Valiev R.K., Rakhaev A.M., Hasanova E.T., Kalova M.R., Nikitin I.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medarhive.ru/jour/article/view/1531

Воспаление является универсальной реакцией живого организма на различные повреждающие факторы и направлено на восстановление целостности тканей и минимизацию гибели клеток. Активными участниками воспалительного ответа являются провоспалительные цитокины, в частности интерлейкины. У пациентов с сердечной недостаточностью воспалительные реакции приводят к повреждению кардиомиоцитов, их апоптозу и активации нейрогуморальных систем, которые способствуют запуску гибернации миокарда и механизмов его ремоделирования. Цель представленного обзора — рассмотреть интерлейкин-1 (IL-1) качестве диагностического и прогностического маркера при сердечной недостаточности, а также влияние лечения рекомбинантной формой IL-1R на течение заболевания.

Inflammation is a universal response of a living organism to various damaging factors and is aimed at restoring tissue integrity and minimizing cell death. Proinflammatory cytokines, in particular interleukins, are active participants in the inflammatory response. In patients with heart failure, inflammatory reactions lead to damage to cardiomyocytes, their apoptosis and activation of neurohumoral systems, which contribute to the initiation of myocardial hibernation and mechanisms of its remodeling. The purpose of this review is to consider IL-1 as a diagnostic and prognostic marker in heart failure, as well as the effect of treatment with a recombinant form of IL-1R on the course of the disease.

воспалениебиологический маркерсердечная недостаточностьцитокиныинтерлейкиныанакинраinflammationbiological markerheart failurecytokinesinterleukinsanakinraReferencesTsao C.W., Lyass A., Enserro D. et al. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC: heart failure. 2018; 6(8): 678-685. DOI: 10.1016/j. jchf.2018.03.006.Tsao C.W., Lyass A., Enserro D. et al. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC: heart failure. 2018; 6(8): 678-685. DOI: 10.1016/j. jchf.2018.03.006.Фомин И.В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016; (8):7-13. DOI: 10.15829/1560-4071-2016-8-7-13.Fomin I.V. Chronic heart failure in the Russian Federation: what we know today and what we must do. Russian journal of cardiology. 2016; (8):7-13. DOI: 10.15829/1560-4071-2016-8-7-13 [in Russian].Maggioni A.P., Dahlström U., Filippatos G. et al. EURObservational Research Programme: regional differences and 1-year followup results of the Heart Failure Pilot Survey (ESC-HF Pilot). European journal of heart failure. 2013;15(7) :808-817. DOI: 10.1093/eurjhf/hft050.Maggioni A.P., Dahlström U., Filippatos G. et al. EURObservational Research Programme: regional differences and 1-year followup results of the Heart Failure Pilot Survey (ESC-HF Pilot). European journal of heart failure. 2013;15(7) :808-817. DOI: 10.1093/eurjhf/hft050.Алиева А.М., Резник Е.В., Гасанова Э.Т. и др. Клиническое значение определения биомаркеров крови у пациентов с хронической сердечной недостаточностью. Архивъ внутренней медицины. 2018; 8(5):333-345. DOI: 10.20514/2226-6704-2018-8-5-333-345.Alieva A.M., Reznik E.V., Hasanova E.T. et al. Clinical significance of the determination of blood biomarkers in patients with chronic heart failure. Archive of Internal Medicine. 2018; 8(5):333-345. DOI: 10.20514 / 2226-6704-2018-8-5-333-345 [in Russian].Гаспарян А.Ж., Шлевков Н.Б., Скворцов А.А. Возможности современных биомаркеров для оценки риска развития желудочковых тахиаритмий и внезапной сердечной смерти у пациентов хронической сердечной недостаточностью. Кардиология. 2020; 60(4):101–108. DOI: 10.18087/cardio.2020.4.n487.Gasparyan A.Zh., Shlevkov N.B., Skvortsov A.A. Possibilities of modern biomarkers for assessing the risk of developing ventricular tachyarrhythmias and sudden cardiac death in patients with chronic heart failure. Kardiologiia. 2020;60(4):101–108. DOI:10.18087/cardio.2020.4. n487 [in Russian].Алиева А.М., Байкова И.Е., Кисляков В.А. и др. Галектин-3: диагностическая и прогностическая ценность определения у пациентов с хронической сердечной недостаточностью. Терапевтический архив. 2019; 91(9):145–149. DOI: 10.26442/00403660.2019.09.000226.Aliyeva A.M., Baykova I.E., Kislyakov V.A. et al. Galactin-3: diagnostic and prognostic value in patients with chronic heart failure. Therapeutic Archive. 2019; 91(9):145–149. DOI: 10.26442/00403660.2019.09.000226. [in Russian].Алиева А.М., Пинчук Т.В., Алмазова И.И. и др. Клиническое значение определения биомаркера крови ST2 у пациентов с хронической сердечной недостаточностью.Alieva A.M., Pinchuk T.V., Almazova I.I. et al. Сlinical value of blood biomarker ST2 in patients with chronic heart failure. Consilium Medicum. 2021; 23(6):522–526. DOI: 10.26442/20751753.2021.6.200606. [in Russian].Алиева А.М., Алмазова И.И., Пинчук Т.В. и др. Фракталкин и сердечно-сосудистые заболевания. Consilium Medicum. 2020; 22(5):83–86. DOI: 10.26442/20751753.2020.5.200186.Alieva A.M., Almazova I.I., Pinchuk T.V. et al. Fractalkin and cardiovascular disease. Consilium Medicum. 2020; 22(5):83–86. DOI: 10.26442/20751753.2020.5.200186. [in Russian].Chow S.L., Maisel A.S., Anand I. et al. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement from the American Heart Association. Circulation. 2017; 135(22): e1054–91. DOI: 10.1161/CIR.0000000000000490.Chow S.L., Maisel A.S., Anand I. et al. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement from the American Heart Association. Circulation. 2017; 135(22): e1054–91. DOI: 10.1161/CIR.0000000000000490.Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood. 1996; 87(6):2095-147.Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood. 1996; 87(6):2095-147.Szekely Y., Arbel Y. A Review of Interleukin-1 in Heart Disease: Where Do We Stand Today? Cardiol Ther. 2018; 7(1):25-44. DOI: 10.1007/s40119-018-0104-3.Szekely Y., Arbel Y. A Review of Interleukin-1 in Heart Disease: Where Do We Stand Today? Cardiol Ther. 2018; 7(1):25-44. DOI: 10.1007/s40119-018-0104-3.Dinarello C.A. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018; 281:8–27. DOI: 10.1111/imr.12621.Dinarello C.A. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018; 281:8–27. DOI: 10.1111/imr.12621.Dinarello C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011; 117(14):3720-32. DOI: 10.1182/blood-2010-07-273417.Dinarello C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011; 117(14):3720-32. DOI: 10.1182/blood-2010-07-273417.Buckley L.F., Abbate A. Interleukin-1 blockade in cardiovascular diseases: a clinical update. Eur Heart J. 2018; 39(22):2063-2069. DOI:10.1093/eurheartj/ehy128.Buckley L.F., Abbate A. Interleukin-1 blockade in cardiovascular diseases: a clinical update. Eur Heart J. 2018; 39(22):2063-2069. DOI:10.1093/eurheartj/ehy128.Dinarello C.A. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol. 2019; 15:612–632. DOI:10.1038/s41584-019-0277-8.Dinarello C.A. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol. 2019; 15:612–632. DOI:10.1038/s41584-019-0277-8.Abbate A., Toldo S., Marchetti C. et al. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. Circ Res. 2020; 126(9):1260-1280. DOI: 10.1161/CIRCRESAHA.120.315937.Abbate A., Toldo S., Marchetti C. et al. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. Circ Res. 2020; 126(9):1260-1280. DOI: 10.1161/CIRCRESAHA.120.315937.Weber A., Wasiliew P., Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal. 2010; 3(105):cm1. DOI: 10.1126/scisignal.3105cm1.Weber A., Wasiliew P., Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal. 2010; 3(105):cm1. DOI: 10.1126/scisignal.3105cm1.Cremer P.C., Kumar A., Kontzias A. et al. Complicated Pericarditis: Understanding Risk Factors and Pathophysiology to Inform Imaging and Treatment. J Am Coll Cardiol. 2016; 68(21):2311-2328. DOI: 10.1016/j.jacc.2016.07.785.Cremer P.C., Kumar A., Kontzias A. et al. Complicated Pericarditis: Understanding Risk Factors and Pathophysiology to Inform Imaging and Treatment. J Am Coll Cardiol. 2016; 68(21):2311-2328. DOI: 10.1016/j.jacc.2016.07.785.Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008; 358(20):2148-59. DOI:10.1056/NEJMra0800239.Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008; 358(20):2148-59. DOI:10.1056/NEJMra0800239.Liu S.J., Zhou W., Kennedy R.H. Suppression of betaadrenergic responsiveness of L-type Ca2+ current by IL-1beta in rat ventricular myocytes. Am J Physiol. 1999; 276(1):H141-8. DOI: 10.1152/ajpheart.1999.276.1.H141.Liu S.J., Zhou W., Kennedy R.H. Suppression of betaadrenergic responsiveness of L-type Ca2+ current by IL-1beta in rat ventricular myocytes. Am J Physiol. 1999; 276(1):H141-8. DOI: 10.1152/ajpheart.1999.276.1.H141.Combes A., Frye C.S., Lemster B.H. et al. Chronic exposure to interleukin 1beta induces a delayed and reversible alteration in excitation-contraction coupling of cultured cardiomyocytes. Pflugers Arch. 2002; 445(2):246-56. DOI:10.1007/s00424-002-0921-y.Combes A., Frye C.S., Lemster B.H. et al. Chronic exposure to interleukin 1beta induces a delayed and reversible alteration in excitation-contraction coupling of cultured cardiomyocytes. Pflugers Arch. 2002; 445(2):246-56. DOI:10.1007/s00424-002-0921-y.Tatsumi T., Matoba S., Kawahara A. et al. Cytokine-induced nitric oxide production inhibits mitochondrial energy production and impairs contractile function in rat cardiac myocytes. J Am Coll Cardiol. 2000; 35(5):1338-46. DOI: 10.1016/s0735-1097(00)00526-xTatsumi T., Matoba S., Kawahara A. et al. Cytokine-induced nitric oxide production inhibits mitochondrial energy production and impairs contractile function in rat cardiac myocytes. J Am Coll Cardiol. 2000; 35(5):1338-46. DOI: 10.1016/s0735-1097(00)00526-xNadar S.K., Shaikh M.M. Biomarkers in Routine Heart Failure Clinical Care. Card Fail Rev. 2019; 5(1):50-6. DOI:10.15420/cfr.2018.27.2Nadar S.K., Shaikh M.M. Biomarkers in Routine Heart Failure Clinical Care. Card Fail Rev. 2019; 5(1):50-6. DOI:10.15420/cfr.2018.27.2Anand I.S., Rector T.S., Kuskowski M. et al. Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial. Circ Heart Fail. 2014; 7(3):418-26. DOI:10.1161/CIRCHEARTFAILURE.113.001036.Anand I.S., Rector T.S., Kuskowski M. et al. Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial. Circ Heart Fail. 2014; 7(3):418-26. DOI:10.1161/CIRCHEARTFAILURE.113.001036.Felker G.M., Fiuzat M., Thompson V. et al. Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes. Circ Heart Fail. 2013; 6(6):1172-9. DOI: 10.1161/CIRCHEARTFAILURE.113.000207.Felker G.M., Fiuzat M., Thompson V. et al. Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes. Circ Heart Fail. 2013; 6(6):1172-9. DOI: 10.1161/CIRCHEARTFAILURE.113.000207.Daniels L.B., Bayes-Genis A. Using ST2 in cardiovascular patients: a review. Future Cardiol. 2014; 10(4):525-39. DOI:10.2217/fca.14.36.Daniels L.B., Bayes-Genis A. Using ST2 in cardiovascular patients: a review. Future Cardiol. 2014; 10(4):525-39. DOI:10.2217/fca.14.36.Van Tassell B.W., Seropian I.M., Toldo S., et al. Interleukin-1β induces a reversible cardiomyopathy in the mouse. Inflamm Res. 2013; (7):637-40. DOI: 10.1007/s00011-013-0625-0.Van Tassell B.W., Seropian I.M., Toldo S., et al. Interleukin-1β induces a reversible cardiomyopathy in the mouse. Inflamm Res. 2013; (7):637-40. DOI: 10.1007/s00011-013-0625-0.Van Tassell B.W., Arena R.A., Toldo S. et al. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS One. 2012; 7(3): e33438. DOI: 10.1371/journal.pone.0033438.Van Tassell B.W., Arena R.A., Toldo S. et al. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS One. 2012; 7(3): e33438. DOI: 10.1371/journal.pone.0033438.Zhu J., Zhang J., Xiang D., et al. Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity. Eur J Pharmacol. 2010; 643(2-3):247-53. DOI: 10.1016/j.ejphar.2010.06.024.Zhu J., Zhang J., Xiang D., et al. Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity. Eur J Pharmacol. 2010; 643(2-3):247-53. DOI: 10.1016/j.ejphar.2010.06.024.Mezzaroma E., Mikkelsen R.B., Toldo S., et al. Role of Interleukin-1 in Radiation-Induced Cardiomyopathy. Mol Med. 2015; 21(1):210-8. DOI:10.2119/molmed.2014.00243.Mezzaroma E., Mikkelsen R.B., Toldo S., et al. Role of Interleukin-1 in Radiation-Induced Cardiomyopathy. Mol Med. 2015; 21(1):210-8. DOI:10.2119/molmed.2014.00243.Ikonomidis I., Lekakis J.P., Nikolaou M. et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation. 2008; 117(20):2662-9. DOI: 10.1161/CIRCULATIONAHA.107.731877.Ikonomidis I., Lekakis J.P., Nikolaou M. et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation. 2008; 117(20):2662-9. DOI: 10.1161/CIRCULATIONAHA.107.731877.Abbate A., Canada J.M., Van Tassell B.W. et al. Interleukin-1 blockade in rheumatoid arthritis and heart failure: a missed opportunity? Int J Cardiol. 2014; 171(3): e125–e126. DOI: 10.1016/j.ijcard.2013.12.078.Abbate A., Canada J.M., Van Tassell B.W. et al. Interleukin-1 blockade in rheumatoid arthritis and heart failure: a missed opportunity? Int J Cardiol. 2014; 171(3): e125–e126. DOI: 10.1016/j.ijcard.2013.12.078.Van Tassell B.W., Arena R., Biondi-Zoccai G. et al. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol. 2014; 113(2):321-327. DOI: 10.1016/j.amjcard.2013.08.047.Van Tassell B.W., Arena R., Biondi-Zoccai G. et al. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol. 2014; 113(2):321-327. DOI: 10.1016/j.amjcard.2013.08.047.Van Tassell B.W., Abouzaki N.A., Oddi Erdle C. et al. Interleukin-1 blockade in acute decompensated heart failure: a randomized, double-blinded, Placebo-Controlled Pilot Study. J Cardiovasc Pharmacol. 2016; 67(6):544–551. DOI: 10.1097/FJC.0000000000000378.Van Tassell B.W., Abouzaki N.A., Oddi Erdle C. et al. Interleukin-1 blockade in acute decompensated heart failure: a randomized, double-blinded, Placebo-Controlled Pilot Study. J Cardiovasc Pharmacol. 2016; 67(6):544–551. DOI: 10.1097/FJC.0000000000000378.Imen T., Salma M., Khouloud C., et al. IL-1β gene polymorphism and serum levels in a Tunisian population with acute heart failure. Biomark Med. 2017; 11(12):1069-1076. DOI:10.2217/bmm-2017-0179.Imen T., Salma M., Khouloud C., et al. IL-1β gene polymorphism and serum levels in a Tunisian population with acute heart failure. Biomark Med. 2017; 11(12):1069-1076. DOI:10.2217/bmm-2017-0179.Aleksova A., Beltrami A.P., Carriere C. et al. Interleukin- 1β levels predict long-term mortality and need for heart transplantation in ambulatory patients affected by idiopathic dilated cardiomyopathy. Oncotarget. 2017; 8(15):25131-25140. DOI:10.18632/oncotarget.15349.Aleksova A., Beltrami A.P., Carriere C. et al. Interleukin- 1β levels predict long-term mortality and need for heart transplantation in ambulatory patients affected by idiopathic dilated cardiomyopathy. Oncotarget. 2017; 8(15):25131-25140. DOI:10.18632/oncotarget.15349.Van Tassell B.W., Canada J., Carbone S. et al. Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). Circ Heart Fail. 2017; 10(11): e004373. 117.004373. DOI: 10.1161/CIRCHEARTFAILURE.Van Tassell B.W., Canada J., Carbone S. et al. Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). Circ Heart Fail. 2017; 10(11): e004373. 117.004373. DOI: 10.1161/CIRCHEARTFAILURE.Butts B., Butler J., Dunbar S.B. et al. ASC Methylation and Interleukin-1β Are Associated with Aerobic Capacity in Heart Failure. Med Sci Sports Exerc. 2017; 49(6):1072-1078. DOI: 10.1249/MSS.0000000000001200.Butts B., Butler J., Dunbar S.B. et al. ASC Methylation and Interleukin-1β Are Associated with Aerobic Capacity in Heart Failure. Med Sci Sports Exerc. 2017; 49(6):1072-1078. DOI: 10.1249/MSS.0000000000001200.Pascual-Figal D.A., Bayes-Genis A., Asensio-Lopez M.C., et al. The Interleukin-1 Axis and Risk of Death in Patients with Acutely Decompensated Heart Failure. J Am Coll Cardiol. 2019; 73(9):1016-1025. DOI: 10.1016/j.jacc.2018.11.054.Pascual-Figal D.A., Bayes-Genis A., Asensio-Lopez M.C., et al. The Interleukin-1 Axis and Risk of Death in Patients with Acutely Decompensated Heart Failure. J Am Coll Cardiol. 2019; 73(9):1016-1025. DOI: 10.1016/j.jacc.2018.11.054.Javan H., Li L., Schaaf C.L. et al. Interleukin 1 receptor antagonism abrogates acute pressure-overload induced murine heart failure. Ann Thorac Surg. 2021: S0003-4975(21)01434-X. Epub ahead of print. DOI: 10.1016/j.athoracsur.2021.07.044.Javan H., Li L., Schaaf C.L. et al. Interleukin 1 receptor antagonism abrogates acute pressure-overload induced murine heart failure. Ann Thorac Surg. 2021: S0003-4975(21)01434-X. Epub ahead of print. DOI: 10.1016/j.athoracsur.2021.07.044.Abbate A., Wohlford G.F., Del Buono M.G. et al. Interleukin-1 blockade with Anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials. Eur Heart J Cardiovasc Pharmacother. 2021 Oct 7: pvab075. Epub ahead of print. DOI: 10.1093/ehjcvp/pvab075.Abbate A., Wohlford G.F., Del Buono M.G. et al. Interleukin-1 blockade with Anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials. Eur Heart J Cardiovasc Pharmacother. 2021 Oct 7: pvab075. Epub ahead of print. DOI: 10.1093/ehjcvp/pvab075.Van Tassell B.W., Buckley L.F., Carbone S. et al. Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2). Clin Cardiol. 2017; 40(9):626-632. DOI: 10.1002/clc.22719.Van Tassell B.W., Buckley L.F., Carbone S. et al. Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2). Clin Cardiol. 2017; 40(9):626-632. DOI: 10.1002/clc.22719.

The authors declare that there are no conflicts of interest present.